Seagen/Pfizer's MOUNTAINEER-03 trial for HER2+ colorectal cancer remains active, not recruiting
The Phase 3 study testing tucatinib plus trastuzumab and mFOLFOX6 against standard chemotherapy regimens in first-line HER2+ metastatic colorectal cancer was last updated November 16, 2026.
This week's registry update covers a single ongoing Phase 3 trial sponsored by Seagen.
- Tucatinib in combination with trastuzumab and mFOLFOX6 is being tested against mFOLFOX6 given with or without either cetuximab or bevacizumab in subjects with HER2+ metastatic colorectal cancer1, known as MOUNTAINEER-03 (NCT05253651). The study is sponsored by Seagen, a wholly owned subsidiary of Pfizer1, and lists an estimated enrollment of 400 participants1. The trial's status is active, not recruiting, with a start date of 2022-10-241 and estimated primary completion of 2027-12-311. The primary outcome measures progression-free survival assessed by blinded independent central review using RECIST version 1.1 criteria1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.